newsfilter
← Latest News
GlobeNewswire·

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting